Pharmaceutical care of patients with gestational diabetes mellitus |
| |
Authors: | Elnour A A El Mugammar I T Jaber T Revel T McElnay James C |
| |
Affiliation: | Clinical Pharmacist, Al Ain Hospital, United Arab Emirates, and Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK; Consultant Diabetologist, Al Ain Hospital, United Arab Emirates; Director of Primary Health Clinics, Al Ain Hospital, United Arab Emirates; Lecturer in Family Medicine, Faculty of Medicine, UAE University, United Arab Emirates, and Director of Primary Health Clinics, Al Ain Hospital, United Arab Emirates; Professor of Pharmacy Practice, Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK |
| |
Abstract: | Rationale, aims and objective To investigate whether the introduction of a programme of optimising drug treatment, intensive education and self‐monitoring of patients diagnosed with gestational diabetes mellitus (GDM) at an early stage (<20 gestational weeks), will improve management outcomes as determined by objective measures of patient knowledge about diabetes, glycaemia control, maternal/neonatal complications, and health‐related quality of life. Methods The study was a randomized, controlled, longitudinal, prospective clinical trial performed at Al‐Ain Hospital, Al‐Ain, United Arab Emirates. Over an 18‐month period, patients diagnosed with GDM were recruited and were randomly assigned to either an intervention or a control group, in a ratio of 3:2. Intervention patients received a structured pharmaceutical care service (including education and introduction of intensive self‐monitoring) while control patients received traditional services. Patients were followed up from time of recruitment until 6 months postnatally at scheduled outpatient clinics. A range of clinical and humanistic outcome measures, including maternal and neonatal complications, were used to assess the impact of the intervention. Results A total of 165 patients (99 intervention, 66 control) completed the study. The intervention patients exhibited a range of benefits from the provision of the programme when compared with control group patients. Statistically significant (P < 0.05) improvements were shown in the intervention group for knowledge of diabetes, health‐related quality of life (as determined by the SF36), control of plasma glucose and HbA1c, maternal complications [e.g. decreased incidence of pre‐eclampsia (5.1% vs. 16.7%), eclampsia (1.0% vs. 7.6%), episodes of severe hyperglycaemia (3.0% vs. 19.7%) and need for Caesarean section (7.1% vs. 18.2%)], and neonatal complications [e.g. decreased incidence of neonatal hypoglycaemia (2.0% vs. 10.6%), respiratory distress at birth (4.0% vs. 15.2%), hyperbilirubinaemia (1.0% vs. 12.1%) and large for gestational age (9.0% vs. 22.7%)]. Conclusion The research provides clear evidence that provision of pharmaceutical care adds value to the management of GDM as exemplified by improved maternal and neonatal outcomes. |
| |
Keywords: | gestational diabetes mellitus health-related quality of life hyperglycaemia patient education pharmaceutical care self-monitoring |
本文献已被 PubMed 等数据库收录! |
|